Evidence map›Paper›PMID 31051172›Full record

ArticleJournal of molecular biology2019

Near-Neighbor Interactions in the NS3-4A Protease of HCV Impact Replicative Fitness of Drug-Resistant Viral Variants.

Nadezhda T Doncheva, Francisco S Domingues, David R McGivern, Tetsuro Shimakami, Stefan Zeuzem, Thomas Lengauer, Christian M Lange, Mario Albrecht, Christoph Welsch

Open access · greenAbstract read
In one paragraph

Article in Journal of molecular biology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.4field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 8 institutions in 5 countries.

Nadezhda T DonchevaDepartment of Computational Biology and Applied Algorithmics, Max Planck Institute for Informatics, Saarbrücken, Germany; Graduate School of Computer Science, Saarland University, Saarbrücken, Germany.
Francisco S DominguesCenter for Biomedicine, European Academy Bozen/Bolzano (EURAC), Bolzano, Italy.
David R McGivernDivision of Infectious Diseases, Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
Tetsuro ShimakamiDepartment of Gastroenterology, Kanazawa University Hospital, Kanazawa, Japan.
Stefan ZeuzemDepartment of Internal Medicine 1, Goethe University Hospital Frankfurt, Frankfurt a.M., Germany.
Thomas LengauerDepartment of Computational Biology and Applied Algorithmics, Max Planck Institute for Informatics, Saarbrücken, Germany.
Christian M LangeDepartment of Internal Medicine 1, Goethe University Hospital Frankfurt, Frankfurt a.M., Germany.
Mario AlbrechtInstitute for Knowledge Discovery, Graz University of Technology, Graz, Austria.
Christoph WelschDepartment of Computational Biology and Applied Algorithmics, Max Planck Institute for Informatics, Saarbrücken, Germany; Department of Internal Medicine 1, Goethe University Hospital Frankfurt, Frankfurt a.M., Germany. Electronic address: christoph.welsch@kgu.de.
University Hospital Frankfurt · DEEurac Research · ITGoethe University Frankfurt · DEGraz University of Technology · ATKanazawa University Hospital · JPMax Planck Institute for Informatics · DESaarland University · DEUniversity of North Carolina at Chapel Hill · US

Funding

Mechanism of Action of Hepatitis C Virus NS5A InhibitorsR21AI115207 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI MCGIVERN, DAVID R · 2015 to 2016
$418k
NIAID NIH HHS R21 AI115207
6 · The paper itself

Abstract

A variety of amino acid substitutions in the NS3-4A protease of the hepatitis C virus lead to protease inhibitor (PI) resistance. Many of these significantly impair the replication fitness of the resistant variants in a genotype- and subtype-dependent manner, a critical factor in determining the probability with which resistant variants will persist. However, the underlying molecular mechanisms are unknown. Here, we present a novel residue-interaction network approach to determine how near-neighbor interactions of PI resistance mutations in NS3-4A can impact protease functional sites dependent on their genomic background. We constructed subtype-specific consensus residue networks for subtypes 1a and 1b from protease structure ensembles combined with biological properties of protein residues and evolutionary amino acid conservation. By applying local and global network topology analysis and visual exploration, we characterize PI resistance-associated sites and outline differences in near-neighbor interactions. We find local residue-interaction patterns and features at protease functional sites that are subtype specific. The noncovalent bonding patterns indicate higher fitness costs conferred by PI resistance mutations in a subtype 1b genomic background and explain the prevalence of Q80K and R155K in subtype 1a. Based on local residue interactions, we predict a subtype-specific role for the protease residue NS3-Q80 in molecular mechanisms related to the assembly of infectious virus particles that is supported by experimental data on the capacity of Q80K variants to replicate and produce infectious virus in subtype 1a and 1b cell culture.

Indexed as

Virus ReplicationAntiviral AgentsDrug Resistance, ViralHepacivirusHepatitis CHumansModels, MolecularProtease InhibitorsProtein ConformationSerine ProteasesViral Nonstructural ProteinsAntiviral AgentsNS3-4A serine protease, Hepatitis C virusProtease InhibitorsSerine ProteasesViral Nonstructural Proteinshepatitis C virusmolecular determinantsresidue networkssubtypeviral variant fitness

Identifiers

PMID31051172
PMCPMC6554042
OpenAlexW2943087944

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.